(Reuters) – Pfizer‘s (NYSE:PFE) chief executive said on Tuesday he would prefer to wait for clarity on U.S. tax reform before engaging in any big deals in order to get a better understanding of any potential acquisition target’s value. The largest U.S. drugmaker has been under increasing pressure from investors and Wall Street to pull […]
Ocular Therapeutix founder & CEO Sawhney to step down | Personnel Moves – June 23, 2017
The president & CEO of Ocular Therapeutix (NSDQ:OCUL), Amarpreet Sawhney, is slated to step down from the company that he helped start in 2006. He will serve as the board’s executive chairman for 1 year, unless he decides to leave earlier. The company wrote in a regulatory filing that “his service will be automatically renewed for […]
Bristol-Myers Squibb launches prefilled syringe option for arthritis drug
Bristol-Myers Squibb (NYSE:BMY) launched a subcutaneous administration option for Orencia, a biologic indicated for moderately to severely active polyarticular juvenile idiopathic arthritis in patients who are at least 2 years old. The prefilled syringe enables physicians, caregivers and patients to administer Orencia at home. Orencia is traditionally administered via IV infusion. “The data supporting this […]
Sanofi promotes Sibold to exec VP of Sanofi Genzyme | Personnel Moves – April 13, 2017
Sanofi (NYSE:SNY) said at the start of April that it promoted Bill Sibold to exec VP of Sanofi Genzyme, effective July 1, 2017. Sibold succeeds Dr. David Meeker, who is slated to leave the company at the end of June. Sibold is the head of Sanofi Genzyme’s global multiple sclerosis, oncology and immunology organization. He […]
Trump FDA pick to recuse himself from agency decisions involving 20 companies
Donald Trump’s nominee to head the FDA, Dr. Scott Gottlieb, reportedly told ethics officials at the Office of Government Ethics he plans to recuse himself for 1 year from agency decisions on more than 20 companies, including GlaxoSmithKline (NYSE:GSK) and Bristol-Myers Squibb (NYSE:BMY). Gottlieb has received millions of dollars for his roles as advisor, paid speaker […]
Sanofi gains on Q4 results; a look at some of the top drug-delivery earners in 2016
Shares in Sanofi (NYSE:SNY) have gained 11% to $44.58 apiece since the company released its 4th-quarter and full year 2016 financial results in February. The French company posted profits of $731.5 million on sales of $8.21 billion for the 3 months ended Dec. 31, for bottom-line growth of 136.5% on sales growth of 3.3% compared with […]
Bristol-Myers prices $1.5B senior notes offering
Bristol-Myers Squibb (NYSE:BMY) said today that it has agreed to sell $1.5 billion of senior unsecured notes in an underwritten public offering. The offering includes $750 million in 1.6% senior notes due in 2019 and $750 million in 3.3% senior notes due in 2027, according to the New York-based company. Bristol-Myers said it plans to […]
Bristol-Myers, PsiOxus land licensing agreement
Bristol-Myers Squibb (NYSE:BMY) said today that it landed an exclusive licensing agreement for PsiOxus Therapeutics‘ ‘armed’ oncolytic virus, NG-348, for the treatment of solid tumors. According to the agreement, Bristol-Myers will pay PsiOxus $50 million upfront and will assume responsibility for global clinical development and commercialization. PsiOxus will be eligible for $886 million in development, regulatory and […]
Tax holiday could ignite more pharma M&A
(Reuters) – U.S. President-elect Donald Trump’s plan to incentivize U.S. companies to repatriate their swelling overseas cash piles could spur a new wave of dealmaking in a pharmaceutical industry seeking to buy its way into growth. For years, big U.S. drugmakers have turned to acquisitions of foreign companies to put their overseas cash to work, […]
Bristol-Myers Squibb, Enterome ink immuno-oncology collab
Bristol-Myers Squibb (NYSE:BMY) said today that it inked a collaboration agreement with Enterome to discover and develop microbiome-derived biomarkers and drug targets as potential companion diagnostics and therapeutics for cancer. According to the agreement, Bristol-Myers Squibb will be given exclusive rights to intellectual property and therapies that result from the collaboration. Enterome will get an […]
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn